Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Other Non Operating Income (2016 - 2025)

Heron Therapeutics' Other Non Operating Income history spans 10 years, with the latest figure at -$2.1 million for Q3 2025.

  • For Q3 2025, Other Non Operating Income fell 428.97% year-over-year to -$2.1 million; the TTM value through Dec 2025 reached -$3.3 million, down 873.49%, while the annual FY2025 figure was -$11.3 million, 2736.98% down from the prior year.
  • Other Non Operating Income reached -$2.1 million in Q3 2025 per HRTX's latest filing, down from -$744000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $2.0 million in Q4 2024 to a low of -$6.9 million in Q2 2022.
  • Average Other Non Operating Income over 5 years is -$541333.3, with a median of -$445000.0 recorded in 2021.
  • Peak YoY movement for Other Non Operating Income: crashed 1156.59% in 2022, then surged 455.25% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at $868000.0 in 2021, then surged by 52.3% to $1.3 million in 2022, then tumbled by 105.98% to -$79000.0 in 2023, then skyrocketed by 2596.2% to $2.0 million in 2024, then crashed by 204.61% to -$2.1 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Other Non Operating Income are -$2.1 million (Q3 2025), -$744000.0 (Q2 2025), and -$519000.0 (Q1 2025).